Medical Oncology
Physician insights on cancer treatment protocols, immunotherapy, targeted therapies, and clinical trial updates.
Recent Discussions
What is the role of liver transplant in NET?
Identifying the role of liver transplant (txp) in NET patients with all the other therapy options available is challenging. I will admit that there have been several years since I last was involved in the care of a patient that actually ended up having a liver txp. That said, I think certain patient...
Would you favor an adjuvant anti-PD-1 inhibitor or dabrafenib/trametinib for stage IIIC/D resected BRAF V600K-mutated cutaneous melanoma?
There are no good, randomized controlled trials in the adjuvant setting for melanoma to answer this question conclusively. But extrapolating from the data in the metastatic setting, where it is quite clear that the "immunotherapy first" approach affords a benefit over the targeted therapy first appr...
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
First, in terms of risk stratification, core binding factor (CBF) AML [whether inv16 or t(8;21)] is considered to be favorable risk by ELN22 even if a FLT3 mutation is present (Döhner et al., PMID 35797463). The incidence of FLT3-ITD in CBF-AML is 5-10% (Faber et al., PMID 27798625). There are some ...
Would you give GO and/or a FLT3 inhibitor for patients with AML with t(8;21) and FLT3-ITD low in addition to 7+3?
First, in terms of risk stratification, core binding factor (CBF) AML [whether inv16 or t(8;21)] is considered to be favorable risk by ELN22 even if a FLT3 mutation is present (Döhner et al., PMID 35797463). The incidence of FLT3-ITD in CBF-AML is 5-10% (Faber et al., PMID 27798625). There are some ...
With the addition of pembrolizumab following chemoradiation per KEYNOTE-A18, would you be less likely to treat the paraaortic chain prophylactically?
I would favor the same volume of RT with or without pembro. If there is an indication to treat PA nodal chain, would treat as per plan.
How would you treat a patient with isolated CNS relapse of seminoma?
As one would expect there are really no reliable data to use to make decisions. I am assuming that there is no significant elevation of HCG or AFP? Typically, I would first recommend engagement of a high-volume center to review details of the case and get guidance. This is a highly unusual setting f...
For which rituximab infusion reaction symptoms do you consider it safe to re-challenge in the office with adjusted rates and pre-medications?
When deciding whether it is safe to re-challenge with rituximab after an infusion reaction, the most important consideration is the type of reaction that the patient experienced. This will help to risk stratify and determine whether same day or future infusions of RTX should be used. Importantly, th...
For which rituximab infusion reaction symptoms do you consider it safe to re-challenge in the office with adjusted rates and pre-medications?
When deciding whether it is safe to re-challenge with rituximab after an infusion reaction, the most important consideration is the type of reaction that the patient experienced. This will help to risk stratify and determine whether same day or future infusions of RTX should be used. Importantly, th...
Would you use sequential CDK 4/6 inhibitors in HR-positive metastatic breast CA in successive lines of therapy?
There is no preclinical or clinical data to support this approach at this time. I would not use sequential therapy in the absence of data. Several studies are ongoing to evaluate whether continued suppression of this pathway in the face of disease progression benefits patients. Until those studies h...
Would you give durvalumab consolidation to a patient with stage III NSCLC with an STK11 mutation?
Short answer: I would.Longer answer: We certainly know that STK11 mutations are associated with worse outcomes with immunotherapy. There are very few data sets and no large datasets that I am aware of that specifically look at this subset of patients with regard to chemoradiation followed by durvalu...